Cambiar Investors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Cambiar Investors LLC has acquired 50,310 shares of Regeneron Pharmaceuticals, valued at approximately $31.9 million, indicating growing interest from institutional investors in the company.
• Regeneron reported a quarterly EPS of $12.89, significantly exceeding analyst expectations of $8.43, reflecting strong performance and a revenue growth of 3.6% year-over-year.
• The company has announced a quarterly dividend of $0.88 per share, translating to an annual yield of 0.6%, with a low dividend payout ratio of 8.87%.

Cambiar Investors LLC acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 50,310 shares of the biopharmaceutical company's stock, valued at approximately $31,908,000.

Several other institutional investors also recently bought and sold shares of REGN. Adirondack Trust Co. raised its holdings in Regeneron Pharmaceuticals by 4.2% in the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after acquiring an additional 18 shares during the last quarter. Kingswood Wealth Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 1.8% in the 1st quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock worth $681,000 after acquiring an additional 19 shares during the last quarter. Creative Financial Designs Inc. ADV raised its holdings in Regeneron Pharmaceuticals by 9.5% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock worth $139,000 after acquiring an additional 19 shares during the last quarter. Private Trust Co. NA raised its holdings in Regeneron Pharmaceuticals by 13.1% in the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock worth $104,000 after acquiring an additional 19 shares during the last quarter. Finally, Proficio Capital Partners LLC raised its holdings in Regeneron Pharmaceuticals by 6.2% in the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock worth $207,000 after acquiring an additional 19 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded down $2.13 during midday trading on Tuesday, hitting $571.78. The company had a trading volume of 854,560 shares, compared to its average volume of 979,587. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The company has a market cap of $60.60 billion, a price-to-earnings ratio of 14.41, a PEG ratio of 1.91 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20. The company has a fifty day moving average of $546.30 and a two-hundred day moving average of $593.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. The firm had revenue of $3,675,600 billion during the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.Regeneron Pharmaceuticals's revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the business posted $11.56 EPS. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on REGN. Rothschild & Co Redburn began coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 price target on the stock. Robert W. Baird dropped their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a report on Friday, April 25th. Royal Bank Of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research note on Monday, August 4th. UBS Group reiterated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Finally, Truist Financial decreased their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $829.65.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.